Show simple item record

dc.contributor.authorRibeiro, S
dc.contributor.authorEiring, AM
dc.contributor.authorKhorashad, JS
dc.date.accessioned2022-01-06T14:45:38Z
dc.date.available10000-01-01
dc.date.issued2021-10-09
dc.identifier.citationCancers, 2021, 13 (20)
dc.identifier.issn2072-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4941
dc.identifier.eissn2072-6694
dc.identifier.doi10.3390/cancers13205055
dc.description.abstractAcute myeloid leukemia (AML) is a highly heterogeneous malignancy characterized by the clonal expansion of myeloid stem and progenitor cells in the bone marrow, peripheral blood, and other tissues. AML results from the acquisition of gene mutations or chromosomal abnormalities that induce proliferation or block differentiation of hematopoietic progenitors. A combination of cytogenetic profiling and gene mutation analyses are essential for the proper diagnosis, classification, prognosis, and treatment of AML. In the present review, we provide a summary of genomic abnormalities in AML that have emerged as both markers of disease and therapeutic targets. We discuss the abnormalities of RARA, FLT3, BCL2, IDH1, and IDH2, their significance as therapeutic targets in AML, and how various mechanisms cause resistance to the currently FDA-approved inhibitors. We also discuss the limitations of current genomic approaches for producing a comprehensive picture of the activated signaling pathways at diagnosis or at relapse in AML patients, and how innovative technologies combining genomic and functional methods will improve the discovery of novel therapeutic targets in AML. The ultimate goal is to optimize a personalized medicine approach for AML patients and possibly those with other types of cancers.
dc.formatElectronic
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleGenomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia.
dc.typeJournal Article
dcterms.dateAccepted2021-10-08
rioxxterms.versionVoR
rioxxterms.versionofrecord10.3390/cancers13205055
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2021-10-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCancers
pubs.issue20
pubs.notesIndefinite
pubs.organisational-group/ICR
pubs.publication-statusPublished
pubs.volume13
pubs.embargo.termsIndefinite
pubs.embargo.date10000-01-01
dc.contributor.icrauthorKhorashad, Jamshiden_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0